Groups Seek to Revoke Narcotic Approval

More than 40 medical and consumer groups are seeking to revoke the recent approval of a new narcotic pill. The drug is Zohydro, a long-acting version of the narcotic hydrocodone. The Food and Drug Administration (FDA) approved the drug in October. The decision went against the advice of the FDA’s own advisory committee. These experts had voted 11-2 against allowing sale of Zohydro. The FDA usually follows the advice of its advisory panels. The groups that filed the petition with the FDA said this new painkiller is too dangerous. The dose is high, and so is the potential for abuse, they said. The petition also said there’s no need for another high-dose prescription narcotic. Public Citizen, one of the groups, said in a news release that a single dose of Zohydro could kill a child. The petitioners also include addiction treatment and other consumer watchdog groups.

Content restricted. Requires subscription

Heart, Stroke Risk Up after Spouse’s Death

The risk of a heart attack or stroke doubles for older adults in the month after they lose a spouse or partner, a new study suggests. The study looked at the medical histories of 2 groups of adults, ages 60 through 89. One group included 30,500 men and women who had lost a spouse or partner between 2005 and 2012. The other group included 83,600 people in the same age group who had not lost a partner. In the month after the partner died, the bereaved person was twice as likely to have a fatal or nonfatal heart attack or stroke as someone who did not have such a loss. But the number of these events was small. And after 90 days the heart attack and stroke rates were about the same in both groups. The journal JAMA Internal Medicine published the study. HealthDay News wrote about it February 24.

Content restricted. Requires subscription

Supplements May Boost Prostate Cancer Risk

Taking vitamin E or selenium pills could double some men’s risk of aggressive prostate cancer, a new study finds. This study took a closer look at some data from a large study that was stopped early, in 2008. Researchers stopped that study because men taking vitamin E pills showed an increased risk of prostate cancer. Selenium pills did not appear to affect prostate cancer risk in that study. The new study focused on 1,739 men from the earlier study who were diagnosed with prostate cancer. They were compared with 3,117 men without prostate cancer. This second group was matched to the first group by age and race. Researchers looked at men’s natural selenium levels, before they took any supplements. For men with high selenium levels, taking selenium pills in the study almost doubled their risk of aggressive prostate cancer.

Content restricted. Requires subscription